PLoS ONE (Jan 2014)

MiR-199a regulates cell proliferation and survival by targeting FZD7.

  • Jiugang Song,
  • Liucun Gao,
  • Guang Yang,
  • Shanhong Tang,
  • Huahong Xie,
  • Yongji Wang,
  • Jingbo Wang,
  • Yanping Zhang,
  • Jiang Jin,
  • Yawen Gou,
  • Zhiping Yang,
  • Zheng Chen,
  • Kaichun Wu,
  • Jie Liu,
  • Daiming Fan

DOI
https://doi.org/10.1371/journal.pone.0110074
Journal volume & issue
Vol. 9, no. 10
p. e110074

Abstract

Read online

A growing amount of evidence indicates that miRNAs are important regulators of multiple cellular processes and, when expressed aberrantly in different types of cancer such as hepatocellular carcinoma (HCC), play significant roles in tumorigenesis and progression. Aberrant expression of miR-199a-5p (also called miR-199a) was found to contribute to carcinogenesis in different types of cancer, including HCC. However, the precise molecular mechanism is not yet fully understood. The present study showed that miR-199a is frequently down-regulated in HCC tissues and cells. Importantly, lower expression of miR-199a was significantly correlated with the malignant potential and poor prognosis of HCC, and restoration of miR-199a in HCC cells led to inhibition of the cell proliferation and cell cycle in vitro and in vivo. Furthermore, Frizzled type 7 receptor (FZD7), the most important Wnt receptor involved in cancer development and progression, was identified as a functional target of miR-199a. In addition, these findings were further strengthened by results showing that expression of FZD7 was inversely correlated with miR-199a in both HCC tissues and cells and that over-expression of miR-199a could significantly down-regulate the expression of genes downstream of FZD7, including β-catenin, Jun, Cyclin D1 and Myc. In conclusion, these findings not only help us to better elucidate the molecular mechanisms of hepatocarcinogenesis from a fresh perspective but also provide a new theoretical basis to further investigate miR-199a as a potential biomarker and a promising approach for HCC treatment.